SynAct Pharma announces Nomination Committee in respect of AGM 2022

Report this content

SynAct Pharma AB (“SynAct”) today announced that the Nomination Committee in preparation for the Annual General Meeting 2022 on May 20, 2022, has been appointed.

Pursuant to the instruction and charter for the Nomination Committee adopted at the Annual General Meeting held on May 21, 2021, the Nomination Committee shall consist of four members, representing the three largest shareholders as per end of September, together with the chairman of the Board of Directors.

Based on the above, the Nomination Committee for the Annual General Meeting 2022 has been established to consist of the following persons:

  • Pernille Singer, appointed by Bioinvest ApS
  • Jens Bager, appointed by GL Capital AB
  • Steen Christensen, appointed by Next Stage Ventures ApS
  • Torbjørn Bjerke, Chairman of the Board of Directors

The members have appointed Jens Bager to be its chairman. In total, the Nomination Committee represents ~20% of the total number of shares and votes in the company.

The Nomination Committee's tasks for the Annual General Meeting 2022 are to propose a Chairman for the Annual General Meeting, members of the Board of Directors and Chairman of the Board of Directors as well as auditor. The Nomination Committee will also propose remuneration to members of the Board of Directors and the auditor. Finally, the Nomination Committee will propose principles for appointing the Nomination Committee (if the Nomination Committee considers that the current principles and instructions should be updated).

Shareholders are welcome to submit their proposals and views to the Nomination Committee to SynAct Pharma AB, Att: Nomination Committee, c/o Medicon Village, Scheelevägen 2, 223 63 Lund, or by e-mail to To ensure that proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but no later than January 31, 2022.

The Nomination Committee's proposals will be announced in the notice for the Annual General Meeting 2022 and on SynAct’s web site.

The information was submitted, through the agency of the contact person below, for publication on November 19, 2021

For further information about SynAct Pharma AB, please contact:  

Jeppe Øvlesen                                    
CEO, SynAct Pharma AB                    
Phone: +45 28 44 75 67                       

Thomas Jonassen
CSO, SynAct Pharma AB
Phone: +45 40 15 66 69


About SynAct Pharma AB 

SynAct Pharma AB conducts research and development in inflammatory diseases. The company has a platform technology based on a new class of drug candidates aimed at acute deterioration in chronic inflammatory diseases with the primary purpose of stimulating natural healing mechanisms. For more information: